Literature DB >> 34489304

Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.

Claire Cook1, Naomi J Patel1,2, Kristin M D'Silva1,2, Tiffany Y-T Hsu2,3, Michael DiIorio2,3, Lauren Prisco3, Lily W Martin3, Kathleen Vanni3, Alessandra Zaccardelli3, Derrick Todd2,3, Jeffrey A Sparks2,3, Zachary Scott Wallace4,2.   

Abstract

Entities:  

Keywords:  COVID-19; autoimmune diseases; epidemiology; vaccination

Mesh：

Substances：

Year:  2021        PMID： 34489304      PMCID： PMC8791428          DOI： 10.1136/annrheumdis-2021-221326

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.

Authors:  Kristin M D'Silva; Naomi Serling-Boyd; Tiffany Y-T Hsu; Jeffrey A Sparks; Zachary S Wallace
Journal:  Ann Rheum Dis       Date:  2021-01-12       Impact factor: 27.973

2.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

3.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

4.  COVID-19 vaccination and antirheumatic therapy.

Authors:  Jack Arnold; Kevin Winthrop; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

5.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

Authors:  Jerald Sadoff; Glenda Gray; An Vandebosch; Vicky Cárdenas; Georgi Shukarev; Beatriz Grinsztejn; Paul A Goepfert; Carla Truyers; Hein Fennema; Bart Spiessens; Kim Offergeld; Gert Scheper; Kimberly L Taylor; Merlin L Robb; John Treanor; Dan H Barouch; Jeffrey Stoddard; Martin F Ryser; Mary A Marovich; Kathleen M Neuzil; Lawrence Corey; Nancy Cauwenberghs; Tamzin Tanner; Karin Hardt; Javier Ruiz-Guiñazú; Mathieu Le Gars; Hanneke Schuitemaker; Johan Van Hoof; Frank Struyf; Macaya Douoguih
Journal:  N Engl J Med       Date:  2021-04-21       Impact factor: 176.079

6.  COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-05-28       Impact factor: 17.586
  6 in total
  25 in total

1.  Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

2.  Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry.

Authors:  Zara Izadi; Milena A Gianfrancesco; Alfredo Aguirre; Anja Strangfeld; Elsa F Mateus; Kimme L Hyrich; Laure Gossec; Loreto Carmona; Saskia Lawson-Tovey; Lianne Kearsley-Fleet; Martin Schaefer; Andrea M Seet; Gabriela Schmajuk; Lindsay Jacobsohn; Patricia Katz; Stephanie Rush; Samar Al-Emadi; Jeffrey A Sparks; Tiffany Y-T Hsu; Naomi J Patel; Leanna Wise; Emily Gilbert; Alí Duarte-García; Maria O Valenzuela-Almada; Manuel F Ugarte-Gil; Sandra Lúcia Euzébio Ribeiro; Adriana de Oliveira Marinho; Lilian David de Azevedo Valadares; Daniela Di Giuseppe; Rebecca Hasseli; Jutta G Richter; Alexander Pfeil; Tim Schmeiser; Carolina A Isnardi; Alvaro A Reyes Torres; Gelsomina Alle; Verónica Saurit; Anna Zanetti; Greta Carrara; Julien Labreuche; Thomas Barnetche; Muriel Herasse; Samira Plassart; Maria José Santos; Ana Maria Rodrigues; Philip C Robinson; Pedro M Machado; Emily Sirotich; Jean W Liew; Jonathan S Hausmann; Paul Sufka; Rebecca Grainger; Suleman Bhana; Wendy Costello; Zachary S Wallace; Jinoos Yazdany
Journal:  ACR Open Rheumatol       Date:  2022-07-22

3.  Evaluation of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Levels in Coronavirus Disease Breakthrough Infection During Immunosuppressive Therapy in a Patient with Connective Tissue Disease-Related Interstitial Lung Disease.

Authors:  Takuma Tsuzuki Wada; Kazuhiro Yokota; Sakon Sakai; Machika Soma; Hiroshi Kajiyama; Norihito Tarumoto; Shigefumi Maesaki; Takuya Maeda; Makoto Nagata; Toshihide Mimura
Journal:  Mod Rheumatol Case Rep       Date:  2022-06-22

4.  Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2021-11-18       Impact factor: 5.732

5.  Immunosuppression and SARS-CoV-2 breakthrough infections.

Authors:  Alfred H J Kim; Jeffrey A Sparks
Journal:  Lancet Rheumatol       Date:  2022-04-29

6.  Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients.

Authors:  L Boekel; G J Wolbink
Journal:  Lancet Rheumatol       Date:  2021-12-23

7.  Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2 ORF3a Transmembrane Protein.

Authors:  Tyng Hwey Tan; Elizabeth Patton; Carol A Munro; Dora E Corzo-Leon; Andrew J Porter; Soumya Palliyil
Journal:  Viruses       Date:  2021-11-02       Impact factor: 5.048

8.  DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study.

Authors:  Michael Di Iorio; Claire E Cook; Kathleen M M Vanni; Naomi J Patel; Kristin M D'Silva; Xiaoqing Fu; Jiaqi Wang; Lauren C Prisco; Emily Kowalski; Alessandra Zaccardelli; Lily W Martin; Grace Qian; Tiffany Y-T Hsu; Zachary S Wallace; Jeffrey A Sparks
Journal:  medRxiv       Date:  2022-02-09

9.  SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.

Authors:  Jean Liew; Milena Gianfrancesco; Carly Harrison; Zara Izadi; Stephanie Rush; Saskia Lawson-Tovey; Lindsay Jacobsohn; Clairissa Ja; Kimme L Hyrich; Laure Gossec; Anja Strangfeld; Loreto Carmona; Martin Schäfer; Elsa Frãzao-Mateus; Inita Bulina; Frances Stafford; Abdurrahman Tufan; Christine Graver; Gözde Kübra Yardımcı; Julija Zepa; Samar Al Emadi; Claire Cook; Fatemah Abutiban; Dfiza Dey; Genevieve Katigbak; Lauren Kaufman; Emily Kowalski; Marco Ulises Martínez-Martínez; Naomi J Patel; Greta Reyes-Cordero; Evelyn Salido; Ellison Smith; David Snow; Jeffrey Sparks; Leanna Wise; Suleman Bhana; Monique Gore-Massy; Rebecca Grainger; Jonathan Hausmann; Emily Sirotich; Paul Sufka; Zachary Wallace; Pedro M Machado; Philip C Robinson; Jinoos Yazdany
Journal:  RMD Open       Date:  2022-04

10.  Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy.

Authors:  Kathleen Mm Vanni; Naomi J Patel; Michael DiIorio; Emily Kowalski; Grace Qian; Claire E Cook; Susan Y Ritter; Zachary S Wallace; Jeffrey A Sparks
Journal:  RMD Open       Date:  2022-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.